Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

APRI 1.44 +0.01 (0.70%)
price chart
Apricus Biosciences, Inc (NASDAQ:APRI) Short Interest Update
Apricus Biosciences, Inc (NASDAQ:APRI) has shown a rise of 0.6% or 14,140 shares in the short positions. The bets have increased to 2,546,679 shares on July 15,2015 from 2,532,539 shares on June 30,2015.
Momentum Stock in Focus: Apricus Biosciences, Inc (NASDAQ:APRI)  Enterprise Leader
Top Growth Pick: Apricus Biosciences, Inc (NASDAQ:APRI)
Apricus Biosciences, Inc (NASDAQ:APRI) has received a top Growth Style score from Zack's Research. The growth score is based on company financials as well as the company's prospects for future growth.
Apricus Biosciences Announces Corporate Update and Second Quarter 2015 ...
(Thomson Reuters ONE via COMTEX) -- SAN DIEGO, July 30, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. APRI, -4.03% a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the ...
Company Shares of Apricus Biosciences, Inc Rally 5.71%
Shares of Apricus Biosciences, Inc (NASDAQ:APRI) rose by 5.71% in the past week and 7.56% for the last 4 weeks. In the past week, the shares has outperformed the S&P 500 by 6.97% and the outperformance increases to 8.39% for the last 4 weeks.
Apricus Biosciences Is Executing Its Strategic Plans (APRI)
For the past few years, Apricus Biosciences, Inc. (NASDAQ:APRI) has attempted to turn its trajectory around and focus on a long-term strategy.
RayVa Patent Award Sends Apricus Biosciences Inc (APRI) Stock Trading Up
Apricus Biosciences Inc. (NASDAQ:APRI) is trading up by around 15.58% as of 11:14 AM EST. The buying spree on the stock followed the announcement from the United States Patent and Trademark Office (USPTO) on Tuesday, awarding the patent to ...
Apricus Biosciences Announces Issuance of U.S. Patent for RayVa(TM)  GlobeNewswire (press release)
Why Apricus With Vitaros Intrigues Investors (APRI)
2015 represents a turning point for Apricus Biosciences (NASDAQ:APRI). Vitaros, the lead product for the treatment of ED, is a topically-applied cream formulation of alprostadil, a vasodilator and NexACT, which directly increases blood flow to the ...
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for ...
SAN DIEGO, May 28, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the launch of Vitaros� in France by Laboratoires ...
Apricus Biosciences And Vitaros: Update On The Launch (APRI)
It's been almost six months since Vitaros was first launched by Apricus Biosciences (NASDAQ:APRI) in the UK, with follow-up launches in Germany, Sweden and Belgium.
Related articles »  
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for ...
SAN DIEGO, May 6, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. APRI, -2.45% a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the launch of Virirec™ in Spain by Recordati.